Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Part of paid clinical trials in Omaha, Nebraska.

Sponsor
University of Nebraska
Study ID
NCT00007865
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • carboplatin — DRUG
  • etoposide — DRUG
  • ifosfamide — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy combined with rituximab in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.

Key Dates

Start date
Sep 1, 2000
Status verified
Dec 2023
Primary completion
Mar 1, 2004
Completion
Apr 22, 2008

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of Nebraska Medical Center, Eppley Cancer CenterOmahaNebraska68198-7680-

Find similar trials in Omaha, NE

By research site
University of Nebraska Medical Center, Eppley Cancer Center· Omaha, NE

Related Studies